Difference between revisions of "Team:Kyoto/Safety"

Line 132: Line 132:
 
     <div id="contents-wrapper">
 
     <div id="contents-wrapper">
 
  <div id="contents">
 
  <div id="contents">
 +
<h6>Contents</h6>
 +
<ul id="toc">
 +
  <li><a href="#safe project design">1 Safe project design</a></li>
 +
  <li><a href="#safe lab work">2 Safe lab work</a></li>
 +
  <li><a href="#safe shipment">3 Safe shipment</a></li>
 +
  <li><a href="#link">4 Link</a></li>
 +
</ul>
 
     
 
     
<h1>Safe project design</h1>
+
<h1 id="safe project design">Safe project design</h1>
 
<ol>
 
<ol>
 
<li>BclA, a protein we have used for surface display, derives from <i>Bacillus anthracis</i> spore protein. <i>Bacillus anthracis</i> creates toxins in human body, and it may cause severe illness. However, the gene coding for BclA protein is unrelated to the toxic genes. In addition, our BclA gene is chemically synthesized using DNA sequence data, and is not refined from <i>Bacillus anthracis</i> genome. </li>
 
<li>BclA, a protein we have used for surface display, derives from <i>Bacillus anthracis</i> spore protein. <i>Bacillus anthracis</i> creates toxins in human body, and it may cause severe illness. However, the gene coding for BclA protein is unrelated to the toxic genes. In addition, our BclA gene is chemically synthesized using DNA sequence data, and is not refined from <i>Bacillus anthracis</i> genome. </li>
 
<li>We will sterilize <i>E. coli</i> before prescription as a medicine because BclA structure does not require <i>E. coli</i> to be viable. This prevents genetically modified <i>E. coli</i> from propagating in natural environment.</li>
 
<li>We will sterilize <i>E. coli</i> before prescription as a medicine because BclA structure does not require <i>E. coli</i> to be viable. This prevents genetically modified <i>E. coli</i> from propagating in natural environment.</li>
 
</ol>
 
</ol>
<h1>Safe lab work</h1>
+
<h1 id="safe lab work">Safe lab work</h1>
 
<ol>
 
<ol>
 
<li>We did not use NoV in experiments for the assessment of scFv. Instead, we used NoV-like particles (NoVLP). It contains only the capsid proteins of the virus and lacks the viral genome, thus not infectious.</li>
 
<li>We did not use NoV in experiments for the assessment of scFv. Instead, we used NoV-like particles (NoVLP). It contains only the capsid proteins of the virus and lacks the viral genome, thus not infectious.</li>
Line 145: Line 152:
 
</ol>
 
</ol>
  
<h1>Safe shipment</h1>
+
<h1 id="safe shipment">Safe shipment</h1>
 
<ol>
 
<ol>
 
<li>Before submission, we have read all related pages in iGEM web page. </li>
 
<li>Before submission, we have read all related pages in iGEM web page. </li>
Line 151: Line 158:
 
</ol>
 
</ol>
  
<h1>Link</h1>
+
<h1 ="link">Link</h1>
 
<ol>
 
<ol>
 
<li>Final Safety form</li>
 
<li>Final Safety form</li>

Revision as of 09:21, 18 October 2016

Contents

Safe project design

  1. BclA, a protein we have used for surface display, derives from Bacillus anthracis spore protein. Bacillus anthracis creates toxins in human body, and it may cause severe illness. However, the gene coding for BclA protein is unrelated to the toxic genes. In addition, our BclA gene is chemically synthesized using DNA sequence data, and is not refined from Bacillus anthracis genome.
  2. We will sterilize E. coli before prescription as a medicine because BclA structure does not require E. coli to be viable. This prevents genetically modified E. coli from propagating in natural environment.

Safe lab work

  1. We did not use NoV in experiments for the assessment of scFv. Instead, we used NoV-like particles (NoVLP). It contains only the capsid proteins of the virus and lacks the viral genome, thus not infectious.
  2. Three of our experimentation members have undergone a safety training session in Kyoto University Institute for Virus Research. They have shared their experiences with all our members.
  3. We have made our own lab safety and management manual.

Safe shipment

  1. Before submission, we have read all related pages in iGEM web page.
  2. We have used submission kits and submitted our parts accordingly.

Link

  1. Final Safety form
  2. https://2016.igem.org/Safety/Final_Safety_Form?team_id=1933
  3. Safety management manual of Kyoto University Graduate School of Science
  4. http://www.sci.kyoto-u.ac.jp/ja/inuniv/safety/_file/safety.pdf